NCT05522361View on ClinicalTrials.gov

Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 6, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 15, 2026

Conditions

Spinal Muscular Atrophy

Interventions

DRUG

Risdiplam

administered to participants per product label insert

Trial Locations (1)

17579

Clinic for Special Children, Strasburg

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Clinic for Special Children

OTHER

NCT05522361 - Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen | Biotech Hunter | Biotech Hunter